T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
RBC Bearings
RBC
$17.5B
| $341M | 0.03% |
1,687,994
+176,831
| +12% | +$38M |
|
427
Chesapeake Utilities
CPK
$3.26B
| $339M | 0.03% |
2,325,402
-48,634
| -2% | -$6.47M |
|
428
Raymond James Financial
RJF
$34.8B
| $339M | 0.03% |
3,374,982
-1,336,730
| -28% | -$132M |
|
429
Xometry
XMTR
$5.42B
| $338M | 0.03% |
6,587,261
+254,784
| +4% | +$13.1M |
|
430
Constellium
CSTM
$3.95B
| $337M | 0.03% |
18,811,179
-313,837
| -2% | -$5.76M |
|
431
Kohl's
KSS
$2.22B
| $336M | 0.03% |
6,796,288
-94,345
| -1% | -$4.82M |
|
432
Idacorp
IDA
$8.16B
| $334M | 0.03% |
2,948,776
+129,798
| +5% | +$13.8M |
|
433
Howmet Aerospace
HWM
$113B
| $330M | 0.03% |
10,356,046
+223,438
| +2% | +$6.89M |
|
434
Otis Worldwide
OTIS
$27.8B
| $327M | 0.03% |
3,756,134
+1,062,743
| +39% | +$89M |
|
435
Sweetgreen
SG
$721M
| $326M | 0.03% |
+10,605,905
| New | +$359M |
|
436
Phreesia
PHR
$780M
| $325M | 0.03% |
7,797,879
-35,726
| -0.5% | -$2.12M |
|
437
Steris
STE
$23B
| $324M | 0.03% |
1,330,970
+554,538
| +71% | +$127M |
|
438
Essex Property Trust
ESS
$18.5B
| $322M | 0.03% |
914,903
+2,891
| +0.3% | +$984K |
|
|
JBTM
439
JBT Marel
JBTM
$6.1B
| $321M | 0.03% |
2,091,589
-114,753
| -5% | -$18M |
|
|
MRTX
440
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $319M | 0.03% |
2,174,799
+60,589
| +3% | +$9.41M |
|
|
PXD
441
DELISTED
Pioneer Natural Resource Co.
PXD
| $314M | 0.03% |
1,726,476
+331,373
| +24% | +$61M |
|
442
Exelixis
EXEL
$12.5B
| $313M | 0.03% |
17,099,967
-137,168
| -0.8% | -$2.62M |
|
443
Quaker Houghton
KWR
$2.95B
| $310M | 0.03% |
1,343,648
-118,138
| -8% | -$28.6M |
|
444
BHP
BHP
$222B
| $309M | 0.03% |
5,738,197
+5,353,212
| +1,390% | +$268M |
|
445
Sanofi
SNY
$105B
| $308M | 0.03% |
6,142,104
+529,723
| +9% | +$26.2M |
|
446
Gen Digital
GEN
$17.7B
| $306M | 0.03% |
11,781,859
+179,435
| +2% | +$4.54M |
|
447
Deckers Outdoor
DECK
$12.7B
| $306M | 0.03% |
5,011,986
+3,095,418
| +162% | +$200M |
|
448
HDFC Bank
HDB
$119B
| $306M | 0.03% |
9,394,000
-169,436
| -2% | -$5.93M |
|
449
Home BancShares
HOMB
$6.27B
| $305M | 0.03% |
12,532,448
-745,503
| -6% | -$18.4M |
|
450
Procore
PCOR
$9.45B
| $303M | 0.03% |
3,793,416
+1,886,628
| +99% | +$165M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.